Condition: Healthy (Controls) · Healthy Volunteers · Neuroendocrine (NE) Tumors · Sponsor: Akiva Mintz
The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET) imaging technique for neuroendocrine tumor detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer that binds to a tumor specific protein called somatostatin receptor 2 (SSTR2) and be imaged on a new type of high sensitivity PET scanner for up to 3 hours
This description comes directly from the study's public registry record.
Barbara Blanchfield · 9732554955 · bblanchfield@nii.org
Dianna Willis, PhD · 973-513-7832 · dewillis@nii.org
Always discuss trial participation with your own doctor first.
| Nuclear Imaging Institute | Englewood, New Jersey, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07284589